Low Molecular Weight Fucoidan Ameliorates Diabetic Nephropathy Via Inhibiting Epithelial-mesenchymal Transition and Fibrotic Processes

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2015 Nov 10

PMID 26550455

Citations 18

Authors

Jihui Chen

Wentong Cui

Quanbin Zhang

Yingli Jia

Yi Sun

Lin Weng

Dali Luo

Hong Zhou

Baoxue Yang

Affiliations

Soon will be listed here.

Abstract

Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes and may lead to end-stage renal disease (ESRD) and chronic renal failure. The aim of this study was to determine whether low-molecular-weight fucoidan (LMWF) can reduce harmful transforming growth factor-β (TGF-β)-mediated renal fibrosis in DN using in vitro and in vivo experimental models. The experimental results showed that LMWF significantly reversed TGF-β1-induced epithelial-mesenchymal transition and dose-dependently inhibited accumulation of extracellular matrix proteins, including connective tissue growth factor and fibronectin. It was found that LMWF significantly reduced blood urea nitrogen and blood creatinine in both type 1 and type 2 diabetic rat models. H&E, PAS and Masson's trichrome staining of kidney tissue showed LMWF significantly reduced renal interstitial fibrosis. Treatment with LMWF significantly increased E-cadherin expression and reduced α-SMA, CTGF and fibronectin expression in both type 1 and type 2 diabetic models. LMWF also decreased the phosphorylation of Akt, ERK1/2, p38 and Smad3 in vitro and in vivo. These data suggest that LMWF may protect kidney from dysfunction and fibrogenesis by inhibiting TGF-β pathway and have the potential benefit to slow down the progression of DN.

Citing Articles

Therapeutic Potential of Oligo-Fucoidan in Mitigating Peritoneal Dialysis-Associated Fibrosis.

Chen Y, Wu M, Huang N, Wu M, Hsu Y, Liao C Mar Drugs. 2024; 22(12).

PMID: 39728104 PMC: 11678284. DOI: 10.3390/md22120529.

Renal Health Through Medicine-Food Homology: A Comprehensive Review of Botanical Micronutrients and Their Mechanisms.

Zhao Y, Song J, Feng R, Hu J, Xu H, Ye M Nutrients. 2024; 16(20).

PMID: 39458524 PMC: 11510533. DOI: 10.3390/nu16203530.

Fucoidan's Molecular Targets: A Comprehensive Review of Its Unique and Multiple Targets Accounting for Promising Bioactivities Supported by In Silico Studies.

Zayed A, Al-Saedi D, Mensah E, Kanwugu O, Adadi P, Ulber R Mar Drugs. 2024; 22(1).

PMID: 38248653 PMC: 10820140. DOI: 10.3390/md22010029.

The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery: A Double-Blind, Randomized, Placebo-Controlled Study.

Tsai H, Yeh Y, Chen P, Chang Y, Chen Y, Su W Integr Cancer Ther. 2023; 22:15347354231187153.

PMID: 37822243 PMC: 10571697. DOI: 10.1177/15347354231187153.

A Cyclopentanone Compound Attenuates the Over-Accumulation of Extracellular Matrix and Fibrosis in Diabetic Nephropathy via Downregulating the TGF-β/p38MAPK Axis.

Tang C, Wang M, Liu J, Zhang C, Li L, Wu Y Biomedicines. 2022; 10(12).

PMID: 36552026 PMC: 9775671. DOI: 10.3390/biomedicines10123270.

References

Zeisberg M, Kalluri R . The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl). 2004; 82(3):175-81. DOI: 10.1007/s00109-003-0517-9. View

Hills C, Squires P . TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol. 2009; 31(1):68-74. DOI: 10.1159/000256659. View

Larue L, Bellacosa A . Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005; 24(50):7443-54. DOI: 10.1038/sj.onc.1209091. View

Fioretto P, Caramori M, Mauer M . The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia. 2008; 51(8):1347-55. DOI: 10.1007/s00125-008-1051-7. View

Bachelder R, Yoon S, Franci C, Garcia de Herreros A, Mercurio A . Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol. 2005; 168(1):29-33. PMC: 2171685. DOI: 10.1083/jcb.200409067. View

Schiller M, Javelaud D, Mauviel A . TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci. 2004; 35(2):83-92. DOI: 10.1016/j.jdermsci.2003.12.006. View

Sharma K, Ziyadeh F . The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol. 1994; 266(6 Pt 2):F829-42. DOI: 10.1152/ajprenal.1994.266.6.F829. View

Srivastava S, Koya D, Kanasaki K . MicroRNAs in kidney fibrosis and diabetic nephropathy: roles on EMT and EndMT. Biomed Res Int. 2013; 2013:125469. PMC: 3780472. DOI: 10.1155/2013/125469. View

Zhou B, Deng J, Xia W, Xu J, Li Y, Gunduz M . Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004; 6(10):931-40. DOI: 10.1038/ncb1173. View

10.

Meng X, Chung A, Lan H . Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond). 2012; 124(4):243-54. DOI: 10.1042/CS20120252. View

11.

Iwano M, Plieth D, Danoff T, Xue C, Okada H, Neilson E . Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002; 110(3):341-50. PMC: 151091. DOI: 10.1172/JCI15518. View

12.

Hernandez-Corona D, Martinez-Abundis E, Gonzalez-Ortiz M . Effect of fucoidan administration on insulin secretion and insulin resistance in overweight or obese adults. J Med Food. 2014; 17(7):830-2. DOI: 10.1089/jmf.2013.0053. View

13.

Jeong Y, Kim Y, Jung Y, Park D, Lee D, Ku S . Low molecular weight fucoidan improves endoplasmic reticulum stress-reduced insulin sensitivity through AMP-activated protein kinase activation in L6 myotubes and restores lipid homeostasis in a mouse model of type 2 diabetes. Mol Pharmacol. 2013; 84(1):147-57. DOI: 10.1124/mol.113.085100. View

14.

Phillips A, Baboolal K, Riley S, Grone H, Janssen U, Steadman R . Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto Kakizaki model of non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 2001; 37(2):400-10. DOI: 10.1053/ajkd.2001.21322. View

15.

Wang J, Liu H, Li N, Zhang Q, Zhang H . The protective effect of fucoidan in rats with streptozotocin-induced diabetic nephropathy. Mar Drugs. 2014; 12(6):3292-306. PMC: 4071577. DOI: 10.3390/md12063292. View

16.

Zhang Q, Li Z, Xu Z, Niu X, Zhang H . Effects of fucoidan on chronic renal failure in rats. Planta Med. 2003; 69(6):537-41. DOI: 10.1055/s-2003-40634. View

17.

Hayashi S, Itoh A, Isoda K, Kondoh M, Kawase M, Yagi K . Fucoidan partly prevents CCl4-induced liver fibrosis. Eur J Pharmacol. 2007; 580(3):380-4. PMC: 2258315. DOI: 10.1016/j.ejphar.2007.11.015. View

18.

Cui W, Zheng Y, Zhang Q, Wang J, Wang L, Yang W . Low-molecular-weight fucoidan protects endothelial function and ameliorates basal hypertension in diabetic Goto-Kakizaki rats. Lab Invest. 2014; 94(4):382-93. DOI: 10.1038/labinvest.2014.12. View

19.

Okada H, Kikuta T, Kobayashi T, Inoue T, Kanno Y, Takigawa M . Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol. 2004; 16(1):133-43. DOI: 10.1681/ASN.2004040339. View

20.

Chen J, Wang W, Zhang Q, Li F, Lei T, Luo D . Low molecular weight fucoidan against renal ischemia-reperfusion injury via inhibition of the MAPK signaling pathway. PLoS One. 2013; 8(2):e56224. PMC: 3572020. DOI: 10.1371/journal.pone.0056224. View